Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide

被引：0
|
作者：
Aseem Anand
Michael J. Morris
Steven M. Larson
David Minarik
Andreas Josefsson
John T. Helgstrand
Peter S. Oturai
Lars Edenbrandt
Martin Andreas Røder
Anders Bjartell
机构：
[1] Lund University,Department of Translational Medicine, Division of Urological Cancers
[2] Memorial Sloan Kettering Cancer Center,Department of Medicine
[3] Weil Cornell Medical College,Department of Radiology
[4] Memorial Sloan Kettering Cancer Center,Department of Radiation Physics, Skåne University Hospital
[5] Lund University,Department of Urology, Institute of Clinical Sciences
[6] Sahlgrenska Academy,Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet
[7] University of Copenhagen,Department of Clinical Physiology, Nuclear Medicine and PET
[8] Copenhagen University Hospital,Department of Nuclear Medicine
[9] Skåne University Hospital,Department of Urology
[10] Skåne University Hospital,undefined
来源：
EJNMMI Research | / 6卷
关键词：
Bone Scan Index (BSI); Imaging biomarker; Bone scan; Enzalutamide; Metastatic castration-resistant prostate cancer (mCRPC);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
    Li, Pei-Yu
    Lu, Ying-Hao
    Chen, Chung-Yu
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [22] ENZALUTAMIDE FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
    Ha, Y-S
    Goodin, S.
    DiPaola, R. S.
    Kim, I. Y.
    DRUGS OF TODAY, 2013, 49 (01) : 7 - 13
  • [23] A correlative biomarker study and integrative prognostic model in chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide
    Fernandez-Perez, Maria P.
    Perez-Navarro, Enrique
    Alonso-Gordoa, Teresa
    Conteduca, Vicenza
    Font, Albert
    Vazquez-Estevez, Sergio
    Gonzalez-del-Alba, Aranzazu
    Wetterskog, Daniel
    Antonarakis, Emmanuel S.
    Mellado, Begona
    Fernandez-Calvo, Ovidio
    Mendez-Vidal, Maria J.
    Climent, Miguel A.
    Duran, Ignacio
    Gallardo, Enrique
    Rodriguez Sanchez, Angel
    Santander, Carmen
    Saez, Maria, I
    Puente, Javier
    Tudela, Julian
    Martinez, Alberto
    Lopez-Andreo, Maria J.
    Padilla, Jose
    Lozano, Rebeca
    Hervas, David
    Luo, Jun
    de Giorgi, Ugo
    Castellano, Daniel
    Attard, Gerhardt
    Grande, Enrique
    Gonzalez-Billalabeitia, Enrique
    PROSTATE, 2023, 83 (04) : 376 - 384
  • [24] Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer
    Miyoshi, Yasuhide
    Yoneyama, Shuko
    Kawahara, Takashi
    Hattori, Yusuke
    Teranishi, Jun-ichi
    Ohta, Jun-ichi
    Takebayashi, Shigeo
    Yokomizo, Yumiko
    Hayashi, Narihiko
    Uemura, Hiroji
    UROLOGIA INTERNATIONALIS, 2017, 99 (04) : 400 - 405
  • [25] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Schmid, Sebastian Christoph
    Geith, Alexander
    Boeker, Alena
    Tauber, Robert
    Seitz, Anna Katharina
    Kuczyk, Markus
    von Klot, Christoph
    Gschwend, Juergen Erich
    Merseburger, Axel Stuart
    Retz, Margitta
    ADVANCES IN THERAPY, 2014, 31 (02) : 234 - 241
  • [26] Safety of Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel: Expanded Access in North America
    Joshua, Anthony M.
    Shore, Neal D.
    Saad, Fred
    Chi, Kim N.
    Olsson, Carl A.
    Emmenegger, Urban
    Scholz, Mark
    Berry, William
    Mukherjee, Som D.
    Winquist, Eric
    Haas, Naomi B.
    Foley, Margaret A.
    Dmuchowski, Carl
    Perabo, Frank
    Hirmand, Mohammad
    Hasabou, Nahla
    Rathkopf, Dana
    PROSTATE, 2015, 75 (08) : 836 - 844
  • [27] Corticosteroids alleviate adverse events associated with enzalutamide in patients with metastatic castration-resistant prostate cancer
    Tamura, Keita
    Matsushita, Yuto
    Watanabe, Hiromitsu
    Motoyama, Daisuke
    Ito, Toshiki
    Sugiyama, Takayuki
    Otsuka, Atsushi
    Miyake, Hideaki
    MOLECULAR AND CLINICAL ONCOLOGY, 2020, 12 (05) : 495 - 500
  • [28] Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
    Sabin Goktas Aydin
    Yasin Kutlu
    Harun Muglu
    Ahmet Aydin
    Ozgur Acikgoz
    Jamshid Hamdard
    Ebru Karci
    Ahmet Bilici
    Omer Fatih Olmez
    Ozcan Yildiz
    Cancer Chemotherapy and Pharmacology, 2024, 93 (1) : 71 - 78
  • [29] Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
    Schalken, Jack
    Fitzpatrick, John M.
    BJU INTERNATIONAL, 2016, 117 (02) : 215 - 225
  • [30] Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
    Aydin, Sabin Goktas
    Kutlu, Yasin
    Muglu, Harun
    Aydin, Ahmet
    Acikgoz, Ozgur
    Hamdard, Jamshid
    Karci, Ebru
    Bilici, Ahmet
    Olmez, Omer Fatih
    Yildiz, Ozcan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (01) : 71 - 78
12345